Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meloxicam - Boehringer Ingelheim

Drug Profile

Meloxicam - Boehringer Ingelheim

Alternative Names: Amelotex; Mobec; Mobic; Mobicox; Movalis; Movatec; Parocin; Tenaron; UH AC 62; UH AC 62 XX; UH AE 62 XX; Uticox

Latest Information Update: 30 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
  • Discontinued Preterm labour

Most Recent Events

  • 06 Nov 2018 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Russia (PO) (NCT03684265)
  • 05 Oct 2018 Boehringer Ingelheim initiates enrolment in a phase I bioavailability and bioequivalence trial in healthy volunteers in Russia (PO, Capsule) (NCT03684265)
  • 25 Sep 2018 Boehringer Ingelheim plans a phase I bioavailability study in Healthy volunteers (PO) (NCT03684265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top